FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164585229> ?p ?o ?g. }

• W2164585229 endingPage "208" @default.
• W2164585229 startingPage "203" @default.
• W2164585229 abstract "Congestive heart failure affects 23 million people worldwide, including 7.5 million in North America (670 000 new cases per year) and 7 million in Europe [1]. Since 10% of those over 65 suffer from systolic left ventricular dysfunction, the number of patients with heart failure will double over the next 25 years. At any time, 10% of the heart failure cohort are categorized Stage D with advanced structural heart disease and symptoms at rest, despite detailed medical and cardiac resynchronization therapy. Twenty percent of these are younger than 65 years of age (around 140 000 in both the USA and Europe). The prognosis of Stage D heart failure is grim. In the REMATCH study, only 8% of the medically treated patients were alive at 2 years and continued to suffer in the interim [2]. A recurrent sentiment expressed by the Stage D patients is that they would sacrifice some duration of survival for a period of symptomatic relief [3]. Cardiac transplantation provides this for a highly selected tiny minority [4]. In contrast, cardiac resynchronization therapy is disappointing. A meta-analysis of 14 trials that randomized resynchronization against medical treatment showed only 59% of the NYHA IV device patients to have borderline symptomatic improvement to NYHA III with no survival benefit [5]. Boyle et al. [6] compared functional outcomes for NYHA IV patients after resynchronization or implantation of a left ventricular assist device (LVAD). At 6 months, resynchronized patients achieved only an additional 6 m in the 6 min walk test (insufficient to affect their daily living) and remained NYHA III or IV. In contrast, LVAD patients improved by 341 m, achieving NYHA I or II status. The study could not be randomized because 90% of the LVAD candidates were bed-bound on intravenous inotropes and could not walk beforehand. Long-term mechanical circulatory support is an increasingly realistic ‘off the shelf’ alternative to cardiac transplantation and an effective solution for those rendered ineligible through common heart failure comorbidities [7–9]. The treatment aims are uncontroversial. The first is to provide symptomatic relief and the second to achieve at least 5-year survival with a good quality of life. The third aim is cost containment by reducing the number of hospital admissions to palliate intolerable levels of breathlessness and fatigue. Hospital events account for $20.9 billion of an overall $35 billion heart failure budget in the USA. The rationale for a blood pump deployment is clear. The failing heart beats more than 120 000 times per day pumping around 7000 l of blood against an increasing afterload. As the heart dilates, the ventricular wall tension, myocardial energy and oxygen consumption increase, while sub-endocardial blood flow decreases. The LVAD unloads the failing ventricle resulting in beneficial structural and functional changes in the diseased myocardium [10–12]. Systemic blood flow returns to physiological levels to preserve the coronary and vital organ perfusion [13]. When native heart contractility and segmental wall motion improve, there is less propensity for intraventricular thrombus formation and thromboembolism. In September 2011, the Society of Thoracic Surgeons and the Food and Drugs Administration (USA) assembled a ‘Think Tank’ to focus on the need for long-term mechanical circulatory support in the USA. The group acknowledged the increasing safety profile and reliability of contemporary implantable rotary blood pumps together with the potential for stem cells to broaden the horizons of heart failure management. A need for 40 000 long-term LVADs per year was predicted, which would account for 50% of the heart failure annual budget. Between 15 and 30% of patients require biventricular support and there is no satisfactory long-term mechanical solution for these patients. The pulsatile total artificial hearts have numerous restrictions which confine their use as a bridge to transplantation [14]. INTERMACS data indicate that all total artificial heart patients are transplanted or dead within 6 months [15]." @default.
• W2164585229 created "2016-06-24" @default.
• W2164585229 creator A5066437447 @default.
• W2164585229 creator A5087980707 @default.
• W2164585229 date "2012-05-30" @default.
• W2164585229 modified "2023-09-26" @default.
• W2164585229 title "Long-term biventricular support with rotary blood pumps: prospects and pitfalls" @default.
• W2164585229 cites W1541936005 @default.
• W2164585229 cites W1965388760 @default.
• W2164585229 cites W1967510595 @default.
• W2164585229 cites W1967907894 @default.
• W2164585229 cites W1970163538 @default.
• W2164585229 cites W1971726573 @default.
• W2164585229 cites W1972078676 @default.
• W2164585229 cites W1972962885 @default.
• W2164585229 cites W1976771512 @default.
• W2164585229 cites W1994383166 @default.
• W2164585229 cites W1997780004 @default.
• W2164585229 cites W2008078341 @default.
• W2164585229 cites W2010798210 @default.
• W2164585229 cites W2012154384 @default.
• W2164585229 cites W2015373223 @default.
• W2164585229 cites W2028599189 @default.
• W2164585229 cites W2028627822 @default.
• W2164585229 cites W2034607344 @default.
• W2164585229 cites W2037739226 @default.
• W2164585229 cites W2039169978 @default.
• W2164585229 cites W2039259191 @default.
• W2164585229 cites W2046216836 @default.
• W2164585229 cites W2052461209 @default.
• W2164585229 cites W2058793877 @default.
• W2164585229 cites W2065220165 @default.
• W2164585229 cites W2070530429 @default.
• W2164585229 cites W2073819811 @default.
• W2164585229 cites W2075972693 @default.
• W2164585229 cites W2076410551 @default.
• W2164585229 cites W2091349813 @default.
• W2164585229 cites W2091780550 @default.
• W2164585229 cites W2097518164 @default.
• W2164585229 cites W2101087179 @default.
• W2164585229 cites W2107991887 @default.
• W2164585229 cites W2109031993 @default.
• W2164585229 cites W2125144203 @default.
• W2164585229 cites W2125294138 @default.
• W2164585229 cites W2126953085 @default.
• W2164585229 cites W2127712294 @default.
• W2164585229 cites W2143289682 @default.
• W2164585229 cites W2151543371 @default.
• W2164585229 cites W2157290116 @default.
• W2164585229 cites W2165140213 @default.
• W2164585229 cites W2165719156 @default.
• W2164585229 cites W4292329040 @default.
• W2164585229 cites W2185646482 @default.
• W2164585229 doi "https://doi.org/10.1093/ejcts/ezs256" @default.
• W2164585229 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22648916" @default.
• W2164585229 hasPublicationYear "2012" @default.
• W2164585229 type Work @default.
• W2164585229 sameAs 2164585229 @default.
• W2164585229 citedByCount "17" @default.
• W2164585229 countsByYear W21645852292013 @default.
• W2164585229 countsByYear W21645852292015 @default.
• W2164585229 countsByYear W21645852292016 @default.
• W2164585229 countsByYear W21645852292017 @default.
• W2164585229 countsByYear W21645852292018 @default.
• W2164585229 countsByYear W21645852292019 @default.
• W2164585229 countsByYear W21645852292023 @default.
• W2164585229 crossrefType "journal-article" @default.
• W2164585229 hasAuthorship W2164585229A5066437447 @default.
• W2164585229 hasAuthorship W2164585229A5087980707 @default.
• W2164585229 hasBestOaLocation W21645852291 @default.
• W2164585229 hasConcept C121332964 @default.
• W2164585229 hasConcept C1276947 @default.
• W2164585229 hasConcept C61797465 @default.
• W2164585229 hasConcept C71924100 @default.
• W2164585229 hasConceptScore W2164585229C121332964 @default.
• W2164585229 hasConceptScore W2164585229C1276947 @default.
• W2164585229 hasConceptScore W2164585229C61797465 @default.
• W2164585229 hasConceptScore W2164585229C71924100 @default.
• W2164585229 hasIssue "2" @default.
• W2164585229 hasLocation W21645852291 @default.
• W2164585229 hasLocation W21645852292 @default.
• W2164585229 hasOpenAccess W2164585229 @default.
• W2164585229 hasPrimaryLocation W21645852291 @default.
• W2164585229 hasRelatedWork W1506200166 @default.
• W2164585229 hasRelatedWork W1995515455 @default.
• W2164585229 hasRelatedWork W2048182022 @default.
• W2164585229 hasRelatedWork W2080531066 @default.
• W2164585229 hasRelatedWork W2604872355 @default.
• W2164585229 hasRelatedWork W2748952813 @default.
• W2164585229 hasRelatedWork W2899084033 @default.
• W2164585229 hasRelatedWork W3031052312 @default.
• W2164585229 hasRelatedWork W3032375762 @default.
• W2164585229 hasRelatedWork W3108674512 @default.
• W2164585229 hasVolume "42" @default.
• W2164585229 isParatext "false" @default.
• W2164585229 isRetracted "false" @default.
• W2164585229 magId "2164585229" @default.
• W2164585229 workType "article" @default.